Serum enterolactone levels and the risk of breast cancer in women with palpable cysts

F. Boccardo, G. Lunardi, P. Guglielmini, M. Parodi, R. Murialdo, G. Schettini, A. Rubagotti

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Low levels of lignans, namely enterolactone, have been reported to be associated with an increased risk of breast cancer in the general female population. We assessed, retrospectively, the relationship between serum enterolactone concentrations and the occurrence of breast cancer in women with palpable cysts. The levels of enterolactone in cryopreserved serum aliquots, obtained from 383 women with palpable cysts at the time of their first cyst aspiration, were measured using a time-resolved fluoroimmunoassay (TR-FIA). After a median follow-up time of 6.5 years (range 0.5-12.75 years), 18 women were found to have developed an invasive breast cancer. Median values of serum enterolactone were significantly lower in women who subsequently developed breast cancer: 8.5 nM/l versus 16.0 nM/l: P=0.04. Odd Ratios (OR) for breast cancer were: 0.36 (P=0.03), 0.57 (P=0.3) and 0.38 (P=0.25) for 25th (8 nM/l), 50th (16 nM/l) and 75th (24 nM/l) percentile values, respectively. The receiver operating characteristic (ROC) analysis showed a satisfactory accuracy for enterolactone as a breast cancer risk indicator (area under the curve (AUC)=0.64: P=0.04). Logistic regression analysis confirmed that the enterolactone concentration had a strong protective effect on the breast cancer risk. These findings may have important clinical implications with regard to interventional diet-focused chemo-preventive trials.

Original languageEnglish
Pages (from-to)84-89
Number of pages6
JournalEuropean Journal of Cancer
Volume40
Issue number1
DOIs
Publication statusPublished - Jan 2004

Fingerprint

Cysts
Breast Neoplasms
Serum
Fluoroimmunoassay
Lignans
2,3-bis(3'-hydroxybenzyl)butyrolactone
ROC Curve
Area Under Curve
Logistic Models
Odds Ratio
Regression Analysis
Diet
Population

Keywords

  • Breast cancer risk
  • Cyst type
  • Enterolactone

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Boccardo, F., Lunardi, G., Guglielmini, P., Parodi, M., Murialdo, R., Schettini, G., & Rubagotti, A. (2004). Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. European Journal of Cancer, 40(1), 84-89. https://doi.org/10.1016/S0959-8049(03)00576-8

Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. / Boccardo, F.; Lunardi, G.; Guglielmini, P.; Parodi, M.; Murialdo, R.; Schettini, G.; Rubagotti, A.

In: European Journal of Cancer, Vol. 40, No. 1, 01.2004, p. 84-89.

Research output: Contribution to journalArticle

Boccardo, F, Lunardi, G, Guglielmini, P, Parodi, M, Murialdo, R, Schettini, G & Rubagotti, A 2004, 'Serum enterolactone levels and the risk of breast cancer in women with palpable cysts', European Journal of Cancer, vol. 40, no. 1, pp. 84-89. https://doi.org/10.1016/S0959-8049(03)00576-8
Boccardo, F. ; Lunardi, G. ; Guglielmini, P. ; Parodi, M. ; Murialdo, R. ; Schettini, G. ; Rubagotti, A. / Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. In: European Journal of Cancer. 2004 ; Vol. 40, No. 1. pp. 84-89.
@article{4a5e8730651047f7b243d5ad57a384ec,
title = "Serum enterolactone levels and the risk of breast cancer in women with palpable cysts",
abstract = "Low levels of lignans, namely enterolactone, have been reported to be associated with an increased risk of breast cancer in the general female population. We assessed, retrospectively, the relationship between serum enterolactone concentrations and the occurrence of breast cancer in women with palpable cysts. The levels of enterolactone in cryopreserved serum aliquots, obtained from 383 women with palpable cysts at the time of their first cyst aspiration, were measured using a time-resolved fluoroimmunoassay (TR-FIA). After a median follow-up time of 6.5 years (range 0.5-12.75 years), 18 women were found to have developed an invasive breast cancer. Median values of serum enterolactone were significantly lower in women who subsequently developed breast cancer: 8.5 nM/l versus 16.0 nM/l: P=0.04. Odd Ratios (OR) for breast cancer were: 0.36 (P=0.03), 0.57 (P=0.3) and 0.38 (P=0.25) for 25th (8 nM/l), 50th (16 nM/l) and 75th (24 nM/l) percentile values, respectively. The receiver operating characteristic (ROC) analysis showed a satisfactory accuracy for enterolactone as a breast cancer risk indicator (area under the curve (AUC)=0.64: P=0.04). Logistic regression analysis confirmed that the enterolactone concentration had a strong protective effect on the breast cancer risk. These findings may have important clinical implications with regard to interventional diet-focused chemo-preventive trials.",
keywords = "Breast cancer risk, Cyst type, Enterolactone",
author = "F. Boccardo and G. Lunardi and P. Guglielmini and M. Parodi and R. Murialdo and G. Schettini and A. Rubagotti",
year = "2004",
month = "1",
doi = "10.1016/S0959-8049(03)00576-8",
language = "English",
volume = "40",
pages = "84--89",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "1",

}

TY - JOUR

T1 - Serum enterolactone levels and the risk of breast cancer in women with palpable cysts

AU - Boccardo, F.

AU - Lunardi, G.

AU - Guglielmini, P.

AU - Parodi, M.

AU - Murialdo, R.

AU - Schettini, G.

AU - Rubagotti, A.

PY - 2004/1

Y1 - 2004/1

N2 - Low levels of lignans, namely enterolactone, have been reported to be associated with an increased risk of breast cancer in the general female population. We assessed, retrospectively, the relationship between serum enterolactone concentrations and the occurrence of breast cancer in women with palpable cysts. The levels of enterolactone in cryopreserved serum aliquots, obtained from 383 women with palpable cysts at the time of their first cyst aspiration, were measured using a time-resolved fluoroimmunoassay (TR-FIA). After a median follow-up time of 6.5 years (range 0.5-12.75 years), 18 women were found to have developed an invasive breast cancer. Median values of serum enterolactone were significantly lower in women who subsequently developed breast cancer: 8.5 nM/l versus 16.0 nM/l: P=0.04. Odd Ratios (OR) for breast cancer were: 0.36 (P=0.03), 0.57 (P=0.3) and 0.38 (P=0.25) for 25th (8 nM/l), 50th (16 nM/l) and 75th (24 nM/l) percentile values, respectively. The receiver operating characteristic (ROC) analysis showed a satisfactory accuracy for enterolactone as a breast cancer risk indicator (area under the curve (AUC)=0.64: P=0.04). Logistic regression analysis confirmed that the enterolactone concentration had a strong protective effect on the breast cancer risk. These findings may have important clinical implications with regard to interventional diet-focused chemo-preventive trials.

AB - Low levels of lignans, namely enterolactone, have been reported to be associated with an increased risk of breast cancer in the general female population. We assessed, retrospectively, the relationship between serum enterolactone concentrations and the occurrence of breast cancer in women with palpable cysts. The levels of enterolactone in cryopreserved serum aliquots, obtained from 383 women with palpable cysts at the time of their first cyst aspiration, were measured using a time-resolved fluoroimmunoassay (TR-FIA). After a median follow-up time of 6.5 years (range 0.5-12.75 years), 18 women were found to have developed an invasive breast cancer. Median values of serum enterolactone were significantly lower in women who subsequently developed breast cancer: 8.5 nM/l versus 16.0 nM/l: P=0.04. Odd Ratios (OR) for breast cancer were: 0.36 (P=0.03), 0.57 (P=0.3) and 0.38 (P=0.25) for 25th (8 nM/l), 50th (16 nM/l) and 75th (24 nM/l) percentile values, respectively. The receiver operating characteristic (ROC) analysis showed a satisfactory accuracy for enterolactone as a breast cancer risk indicator (area under the curve (AUC)=0.64: P=0.04). Logistic regression analysis confirmed that the enterolactone concentration had a strong protective effect on the breast cancer risk. These findings may have important clinical implications with regard to interventional diet-focused chemo-preventive trials.

KW - Breast cancer risk

KW - Cyst type

KW - Enterolactone

UR - http://www.scopus.com/inward/record.url?scp=0346996531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346996531&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(03)00576-8

DO - 10.1016/S0959-8049(03)00576-8

M3 - Article

C2 - 14687793

AN - SCOPUS:0346996531

VL - 40

SP - 84

EP - 89

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 1

ER -